fda semaglutide compounding warning november 2025 alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products Congress Introduces SAFE Drugs Act

It was never intended as a target for someone actively losing weight on a GLP-1 receptor agonist

Who Is Most at Risk of Hypoglycaemia on Retatrutide Patients concurrently taking sulphonylureas or insulin, those with renal impairment, older adults, and individuals significantly reducing caloric intake due to appetite suppression are at greatest risk of hypoglycaemia on retatrutide

The new frozen food brand called Vital Pursuit will consist of 12 portion-controlled meals, high in protein plus fiber, intended to be a companion for GLP-1 weight loss medication users and consumers focused on weight management, the company announced Tuesday

More importantly, the weight loss associated with GLP-1s is not a welcome symptom in a disease were slowly progressive wasting is common concern